NCM·Healthcare·$151M·#352 / 520 in Healthcare
GALT Galectin Therapeutics Inc.
34HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY50
VALUATION50
GOVERNANCE91
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
9 months
25
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-106.0%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
N/A
50
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
29.1%
99
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+4.0%
76
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE GALT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when GALT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.